Edward Lin, MD
Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Clinical Title: A Randomized Phase II study of Two-Step ADAPT Therapy with Capecitabine and Celecoxib for Patients with Metastatic Colorectal Cancer
Description: A multi-center randomized phase II trial of ADAPT therapy vs standard of care for patients with metastatic colorectal cancer.
Colorectal cancer is a common and deadly cancer. The chief cause of treatment failure is due to the presence of cancer stem cells. The cancer stem cells go into hibernation during chemotherapy and 'wake up' when chemotherapy is withdrawn or the tumor cells become tolerant to drugs. To target the cancer stem cells is by activating these cells from dormancy and priming them for subsequent targeting.
In this phase II clinical trial, Dr. Lin is studying the effects of his two step ADAPT therapy on metastatic colorectal cancer patients. Dr. Lin's unique therapy combines two drugs: Xeloda (chemotherapy drug) with Celebrex a nonsteroidal anti-inflammatory drug that is often used for treating arthritis. It is the unique combination of these two drugs that has improved the outcome of colorectal cancer by targeting the cancer stem cells.
"We're using the Gateway funding to prospectively prove that you can induce complete remission in patients with colon cancer," said Dr. Lin.
Further, this phase II colon cancer study will determine if specific biologic markers can help predict which patients are likely to respond to the ADAPT therapy.
Status: Active Trial
Accepting Patients? Yes
NIH Clinical Trial Link: http://clinicaltrials.gov/ct2/show/NCT01729923?term=edward+lin&rank=1
One American dies every 57 seconds from cancer.
These are loved ones, not statistics.
Demanding it all!
Funding innovative cancer research for
Treatments. Cures. Life.